Distribution and Marketing of drugs in South Africa
A Q&A guide to distribution and marketing of drugs law in South Africa.
The Q&A gives a high level overview of distribution and marketing of drugs law, including pre-conditions for distribution; licensing; wholesale distribution; marketing to consumers; marketing to professionals and engagement with patient organisations.
To compare answers across multiple jurisdictions, visit the Distribution and Marketing of Drugs Country Q&A Tool.
This Q&A is part of the global guide to Distribution and Marketing of Drugs.
Pre-conditions for distribution
The distribution of medicines in South Africa is governed strictly by:
The Medicines and Related Substances Act No.101 of 1965, as amended (Medicines Act).
Other pieces of legislation governing the movement of medicines in the supply chain and persons authorised to distribute medicines within the supply chain including the:
Pharmacy Act No. 53 of 1974, as amended;
Health Professions Act No.56 of 1974, as amended (HPA).
The distribution of medicine requires a licence that must be obtained from the Medicines Control Council (MCC). The MCC also issues licences to wholesalers, importers and retailers of medicines.
The use of medicines outside of the licensing regime is permitted in certain circumstances for compassionate use (see Question 2). The MCC can use its discretion to decide whether or not:
To grant a licence.
A medicine can be sold.
Access to medicines in a compassionate use programme is granted on a case- by-case basis. Therefore, there are no named compassionate use systems, models or programmes that rely on named patients or any other basis.
However, the Medicines Control Council (MCC) has the right to use its discretion to allow compassionate use of unlicensed medicines or medicines by unlicensed persons. Pre-launch access is required, and access to an unlicensed medicine or to a medicine by an unlicensed person must be approved by the MCC.
Failure to obtain approval will result in an offence under the Medicines Act. For further information see the requisite application form at www.mccza.com/genericdocuments/6.12_section_21_application_form_feb04_v1_1.doc.
The structure for the procedure is set out in the Medicines Act. The Medicines Act (read together with the General Regulations) provides details about the particular forms, application fees and information as required by the Medicines Control Council (MCC).
Licensees are required to provide the requisite information in the application forms and also provide information that is stipulated in the General Regulations regarding the substance to be licensed. The application is then delivered to the MCC and deliberated by the MCC. A decision is then made about whether or not to license the medicine for distribution, and the implementation of conditions that will be applicable to the medicine for distribution purposes (including its scheduled status).
The MCC is responsible for the licensing of drugs in South Africa.
Simplified or expedited licensing procedures exist under section 15 of the Medicines Act. However, the regimes are not really used in practice, due to frequent delays at the Medicine Control Council (MCC) in relation to the processing of licence applications.
There are provisions in the Medicines Act for parallel imports to be accepted, provided that the Minister of Health, (who is ultimately responsible for the enforcement of the Medicines Act) agrees to the parallel import based on a need or requirement of public health. Section 15C of the Medicines Act provides that:
Any patented medicine can be imported if already registered in South Africa.
A person or company that wishes to import a patented medicine must apply to the Minister of Health for a permit to parallel import a medicine.
The holder of a certificate of registration for a medicine in South Africa is not entitled to prevent the medicine's importation into South Africa or its sale, on account of the certificate of registration or the existence of a patent on the medicine.
The parallel importer is responsible and liable for the parallel imported medicines, for example, he must notify the MCC in the event of a recall or adverse event.
The parallel importer is responsible for destroying any expired, parallel imported medicines (for the duration of the permit and also after the parallel importation permit has expired).
Section 15C of the Medicines Act has not been used to date.
There is no specific provision contained in the Medicines Act or any other piece of legislation regarding the virtual distribution of medicines. The Medicines Act assumes that all factors and elements of the distribution of the medicine are physically present within South Africa, including the distributor and the substance being distributed.
It is unlikely that the Medicine Control Council (MCC) would recognise virtual drug distribution. This is because the structure of the Medicines Act provides the MCC with direct jurisdictional control over the process of distributing and selling medicines in South Africa.
There is an appeal provision within the Medicines Act that allows applicants for a licence to appeal the decisions of the Medicine Control Council (MCC) if they are dissatisfied with the outcome of the application. The appeal provisions are strengthened by the provisions relating to procedurally fair administrative law contained in section 33 of the Constitution of the Republic of South Africa, 1996, read together with the:
Provisions of the Promotion of Administrative Justice Act No.3 of 2000.
Various pronouncements in the common law, most notably by the Constitutional Court of South Africa.
The appeal procedure is governed by the provisions of the General Regulations provided in relation to the Medicines Act. Any person aggrieved by a decision of the MCC can appeal under section 24 of the Medicines Act.
The costs will vary depending on the nature of the licence that is required. The costs are published, from time to time, by the Medicine Control Council (MCC) in the Government Gazette. The Government Gazette must be consulted when the licence application is made to the MCC with regard to the costs of a particular licence.
Distribution to consumers
The categories of the medicines are determined by the Medicine Control Council.
The primary method for categorising medicines is based on schedules that range from Schedule 0 to Schedule 7. Various conditions attach to the distribution and sale of the medicine depending on the nature of the schedule that is applied. For example:
Schedule 0 medicines are available off the shelf or without prescription in a supermarket.
Schedule 5 medicines are only available from a pharmacist on prescription by an authorised prescriber.
The sale of medicines to consumers is determined by:
Section 22C of the Medicines Act. A person holding a dispensing licence can sell medicines to consumers.
Pharmacy Act. A person who is registered as a pharmacist can sell medicines directly to consumers.
Certain categories of medicines can be sold directly to consumers "off the shelf" and can be sold by anyone including retailers. The licensing requirements under the Medicines Act provide that:
A written application must be made.
The applicant must adhere to certain criteria as determined by the Medicine Control Council.
The sale of over-the-counter medicines to consumers is restricted to pharmacists who are licensed and registered under the provisions of the Pharmacy Act, and persons licensed under the provisions of section 22C of the Medicines Act. It should be noted that corporate ownership of pharmacies is permitted in terms of section 22A of the Pharmacy Act, provided that the existence of a pharmacy, within the confines of, for example, a retailer or other non-pharmacy setting, is governed by provisions in the Medicines Act and supervised by the Department of Health.
The sale of over-the-counter medicines to consumers is restricted to:
Pharmacists who are licensed and registered under the provisions of the Pharmacy Act.
Persons licensed under the provisions of section 22C of the Medicines Act (see above).
Corporate ownership of pharmacies is allowed under section 22A of the Pharmacy Act, provided that the existence of a pharmacy is governed by provisions in the Medicines Act and supervised by the Department of Health.
Any substance that is registered as a medicine under the provisions of the Medicines Act is available for sale or distribution by an attending physician and can be provided to a consumer/patient by an attending physician.
The Medicines Act and the Pharmacy Act allow for the sale of medicines by attending physicians in circumstances where the medicine is needed to treat the consumer/patient's condition and the attending physician completes the correct prescription for the sale of that medicine. However, a generic substitution is required by law where a generic alternative exists for a branded or prescribed medicine.
Authorised prescribers can prescribe medicines under the provisions of the Medicines Act and the Health Professions Act No.56 of 1974 (HPA). The term "authorised prescriber" is defined in the HPA and recognised by the Medicines Act as persons who are admitted as medical practitioners.
The following persons are allowed to prescribe medicines:
Other persons authorised in accordance with the licensing provisions of the Medicines Act and the Pharmacy Act read together with the HPA.
Distance selling of medicines is permitted, and various courier-type pharmacies exist that specialise in the movement of medicines across large distances. Typically, such arrangements exist within the context of private medical funding. Therefore, a medical scheme (being the vehicle for private medical funding) generally has an arrangement with a courier pharmacy that creates an obligation on the pharmacy to transport medicines within South Africa.
Cross-border sales are not normally authorised unless the:
Receiving state has authorised the entry of medicines into the country through its own licensing regimes.
Persons operating the importation of medicines into that state are authorised and licensed accordingly.
In addition, under the Pharmacy Act, the distributor must be licensed to move medicines over distances, in a courier format.
There are various legal consequences for a person who does not have the correct licence to distribute medicines or who sells medicines in circumstances that contravene the Medicines Act, the Pharmacy Act or the Health Professions Act No.56 of 1974 (HPA).
Penalties include civil and criminal liability. The level of fine or imprisonment will depend on the nature of the offence and the statutory requirement that has been violated. In addition, persons who endanger consumers/patients through the sale of medicines without the appropriate licenses can also contravene the Consumer Protection Act No.68 of 2008 (CPA). The CPA provides for additional penalties.
The wholesale of medicines is governed by the Medicines Act and a licensing structure imposed by the Medicine Control Council (MCC). Any person who wishes to engage in the wholesale of medicines must be licensed to do so by the MCC in accordance with the requirements contained in the Medicines Act and the General Regulations provided in the Medicines Act. Any person can apply to be a wholesaler of medicines subject to requirements that prohibit the existence of a wholesale licence within certain commercial companies that have a direct or indirect beneficial interest in a retail pharmacy.
The Medicine Control Council (MCC) is responsible for supervising wholesale distribution activities.
The MCC is empowered through an inspectorate, created by virtue of provisions in the Medicines Act, to ensure that wholesale activities occur within the confines of the law.
Rights of appeal
A person has a legal right under the Medicines Act to appeal any decisions made by the MCC or its inspectorate. The right to appeal is reinforced by the:
Administrative law provisions set out in section 33 of the Constitution.
Provisions of the Promotion of Administrative Justice Act No.3 of 2000.
Applicable pronouncements in the common law including those by the Constitutional Court of South Africa.
The Medicines Act and its Regulations, govern the marketing of medical substances and devices in South Africa. The Code of Marketing Practice (Code) and its Guidelines provided under the Medicines Act were drafted to regulate the ethical marketing of medicines and medical devices in South Africa.
In particular, the Code regulates:
The marketing and promotion of medical devices and in vitro diagnostics (IVDs).
The marketing and promotion of registered health products (including scheduled and unscheduled medication).
All advertising and promotional activities where members of the medical field are influenced to purchase, prescribe, supply, administer, loan or lease a health product.
Limits to marketing activities
The Medicines Act provides that no person can advertise any medicine or scheduled substance for sale unless the advertisement complies with the prescribed requirements. The Medicines Act also prohibits the publication or distribution of any false or misleading advertisement relating to any medicine.
The Regulations under the Medicines Act provide that only the following can be advertised to the public:
Medicines that do not contain a scheduled substance.
Medicines that contain a substance appearing in Schedule 0 or Schedule 1 (seeQuestion 8).
Medicines that contain a substance appearing in Schedules 2 to 6 (see Question 8) can be advertised for information purposes to:
Pharmacists and other persons authorised to prescribe medicines.
Persons in receipt of certain publications containing the advertising.
The Code deals with the appropriate advertising of medicines and regulates:
Inducements, gifts and promotional items and competitions.
In general, advertisements must not be misleading or disparaging (either directly or by implication). Information, claims and comparisons must be accurate, balanced, fair, objective, unambiguous and supportable and must be based on an up-to-date evaluation of all the evidence and reflect that evidence clearly. The use of medical terminology is acceptable provided that it does not confuse or mislead the consumer.
The Code of Marketing Practice (Code) was drafted by the Marketing Code Authority (MCA) and is supported by the Department of Health. The Code is updated from time to time to reflect developments in the law.
The Code is enforced by the MCA, which is also the body responsible for adjudicating complaints and disputes relating to the Code. The Code is based on the principle of self-regulation through the health industry. However, it is legally binding, as national legislation recognises the self-regulatory Code's principles and procedures.
The Code is adopted by companies in the health industry, for example, the health products trade associations and the South African Medical Device Industry Association, in order to ensure that the marketing of health products to healthcare professionals (HCP) and the public is carried out in a reasonable, ethical and professional manner, based on information that is practical and scientifically validated.
Marketing to consumers
The Medicines Act and the Code of Marketing Practice (Code) govern the marketing of medicinal products to consumers.
The Consumer Protection Act of 2008 (CPA) promotes and advances the social and economic welfare of South African consumers. The CPA:
Is applicable to all goods marketed for human consumption.
Prohibits the application of a trade description to a product that is likely to mislead consumers.
Provides that goods cannot be marketed in such a way that is reasonably likely to imply a false or misleading representation. When marketing a product, a supplier:
cannot make a false, misleading or deceptive representation to consumers regarding the material facts relating to a product; and
must correct any misapprehension on the part of consumers.
The Advertising Standard Authority Code (ASA Code) is the guiding document of the Advertising Standard Authority of South Africa and mainly regulates commercial advertising in South Africa. The Preamble of the ASA Code provides that advertising must be:
The provisions of the ASA Code and the CPA are incorporated to a great extent in the Code and the Medicines Act and its Regulations. For this reason, only the relevant portions of the Code and the Medicines Act are discussed further. However, a complainant is not prohibited from seeking relief under the CPA and the ASA Code, if it believes that the marketing of a medicine contravenes any of the relevant provisions.
The ASA has recently applied to be accredited as an ombudsman scheme for the advertising and marketing industry under the CPA. In July 2016, a proposed Industry Code (the Advertising and Marketing Industry Code of Practice) was published for public comment. It appears that the Industry Code (when finalised and enacted) will replace the ASA Code. The scope of the proposed Industry Code is wide enough to extend to the advertising and marketing of pharmaceuticals and medical devices, but it remains to be seen which amendments will be made to the Code before it is finalised and accepted.
The following can be advertised to the public:
Medicines that do not contain a scheduled substance.
Medicines that contain a substance appearing in Schedule 0 or Schedule 1 (see Question 8).
The Medicines Act
Under the Medicines Act, the term "advertisement" includes any written, pictorial, visual or other descriptive matter or verbal statement or reference that is intended to promote the sale of that medicine or scheduled substance by:
Appearing in any newspaper, magazine, pamphlet or other publication.
Being distributed to members of the public.
Being brought to the notice of members of the public in any manner whatsoever.
The term "advertise" has a corresponding meaning.
The Code of Marketing Practice (Code)
Advertising and/or promotion and promotional materials or activities, includes the following:
Branded materials relating to product sponsorship.
Aerial promotions, for example hot air balloons.
Direct mail materials.
Website and other internet materials, including press releases intended for internet publication.
Point of sale materials and posters.
Print advertisements (for example, for use in newspapers and magazines).
Promotional aids including those used for direct selling activities.
In the marketing and/or advertising of Schedules 0 and 1 medicines (see Question 8), the Code provides that advertisements to the general public must be consistent with the requirements of the Medicines Act and other applicable legislation. Compliance with the Medicines Act includes that all advertising and/or promotional material:
Must give the information necessary for the correct use of a product as approved by the medicines regulatory authority.
Cannot deviate from, be in conflict with or go beyond the evidence submitted in the application for registration of the medicine (and that has been approved by the Medicines Control Council and incorporated in the approved package insert).
Must not be misleading or disparaging (either directly or by implication).
Must not be misleading as to the nature of the product, its ingredients or indications.
Must not contain any other express or implied exaggerated claims as to the benefits that can be obtained from use of the health product.
Must not cause consumers unwarranted anxiety with regard to any condition.
Must not use language which causes fear or distress.
Must not suggest that using a health product can enhance normal good health or be a substitute for a healthy diet and lifestyle.
Must not be aimed principally or exclusively at children (under 12 years of age).
Must not show children using, or within reach of health products without adult supervision.
Must not encourage individuals to exclusively self-diagnose, particularly where medical intervention is required.
Must not encourage consumers to discontinue the use of prescribed health products.
Must not include a recommendation by a person who, because of his celebrity status, can encourage consumers to use a particular health product.
Advertising and/or promotion must not unfairly defame or discredit (either directly or by implication) a competitor product, ingredient or treatment type, or suggest that a product's effects are better than or equal to another identifiable product or treatment.
Testimonials are allowed, provided that the testimonial complies with the approved package insert and the testimonial is not more than three years old. The use of healthcare professionals (HCPs) for marketing, promotion, endorsements or testimonials is allowed, provided that it takes place within the scope set by the professional codes applicable to such professionals.
The Medicines Act
Part A of the Code of Marketing Practice (Code), which deals with the marketing of health products to healthcare professionals (HCPs), prohibits the supply of samples beyond the conditions provided under the Medicines Act.
The Medicines Act provides that no person must provide a sample of any medicine. A "sample" means the free supply of medicines by a manufacturer or wholesaler or its agent to a pharmacist, medical practitioner, dentist, veterinarian, practitioner, nurse or other person registered under the Health Professions Act 1974. It does not include the free supply of medicines for the purposes of clinical trials, donations of medicines to the state, tendering to the state and quality control by inspectors. Part A of the Code does not expressly prohibit the provision of free samples to consumers.
The Code provides that the provision of medical goods that will enhance patient care or benefit the South African health system are acceptable. The provision of such goods must not be done in such a way as to be an inducement to prescribe, supply, administer or buy any health product or to recommend its use, prescription or purchase. However, it is unclear if the term "medicinal goods" means medicines or if it relates to medical equipment or promotional items, for example, desk pads and pens.
The Code provides that banded packs for Schedule 0 medicinal products (see Question 8) are permitted. The medicinal products that are banded together must be the same product that is two lots of product "X" lozenges.
It is not permissible to band together different dosage forms or products (that is product X syrup and product X lozenges).
Giveaway items, for example plastic dosage spoons for Schedule 0 products must be of a nominal value and not mislead the patient or encourage the inappropriate use of the health product.
The branding of children's medicines must not advertise or encourage the use of medicines by children.
The advertising of Schedules 0 and 1 medicines to the public is permitted. Therefore, E-pharmacies are restricted to the promotion and online sale of Schedule 0 and Schedule 1 medicines.
The Code of Marketing Practice (Code) provides that internet access to promotional materials of Schedule 2 to Schedule 6 medicine that is directed at the South African public must be limited through a password protection scheme to healthcare professionals (HCPs).
Information or promotional material relating to Schedule 2 to Schedule 6 medicines that is placed on the internet outside of South Africa will be regarded as falling within the scope of the Code if:
It was placed on the internet by a South African company or an affiliate of a South African company, or at the instigation or with the authority of a South African company or an affiliate of a South African company.
It makes specific reference to the availability or use of the medicine in South Africa.
Schedule 2 to Schedule 6 medicines can be advertised in relevant, independently produced electronic journals that are intended for HCPs or appropriate administrative staff, provided that the electronic journals cannot be accessed by non-HCPs.
Package inserts of Schedule 2 to Schedule 6 medicines can be made available on the internet and accessed by members of the public, provided that the package inserts are not presented in such a way as to be promotional in nature.
In addition, it must be made clear to an internet user:
That he is leaving any of the company sites.
When he is leaving any sites sponsored by the company.
That he is being directed to a site that is not that of the company.
The promotion of all medicines by e-mail is prohibited, unless the option to opt out is given and the decision is respected. The opt out option must also be provided on all subsequent communications, even if the addressee has not opted out after the first point of contact.
The Medicines Control Council (MCC) is the body authorised to supervise the marketing of medicines under the Medicines Act. For information relating to the establishment of the South African Health Products Regulatory Authority (SAHPRA), which will replace the MCC in due course, see Question 35.
The Code of Marketing Practice (Code) is enforced by the Marketing Code Authority (MCA), which is also responsible for settling complaints and disputes under the Code. The Code is based on the principle of self-regulation through the health industry. However, it is considered legally binding, as national legislation recognises the self-regulatory Code's principles and procedures.
The Medicines Act. The MCC is empowered through an inspectorate, created in accordance with the Medicines Act, to ensure that wholesale distribution activities occur within the confines of the law.
Under the Medicines Act, an inspector can enter any premises if he suspects, on reasonable grounds that an offence under the Medicines Act is being, or may be committed in the future. The inspector can also inspect any medicine or scheduled substance, any book, record or documents that he believes, on reasonable grounds, to contain any information relevant to the administration or enforcement of the Medicines Act.
The Code. The MCA can process any dispute or complaint relating to the provisions of the Code, and an aggrieved party can, after exhausting all internal remedies in the Code, approach the MCC for resolution of the matter. The MCA also has the authority to refer any matter to the MCC if it considers that the matter warrants the referral.
Rights of appeal
Under the Medicines Act, any person aggrieved by a decision of the MCC can appeal against the decision to an appeal committee.
Under the Code, it is possible to appeal against the decision of the Adjudication Committee. Appeals can, at the discretion of the Adjudication Committee, and depending on the complexity of the matter, be a face-to-face hearing, or a paper-based appeal. A decision against the Adjudication Committee must lie with an Appeal Committee and no other body.
The Medicines Act
It is an offence to contravene the provisions of the Medicines Act, including those that prohibit the misleading advertising of medicines. Any person who is convicted of an offence will be liable to a fine, or to imprisonment for a period of up to ten years.
The court that convicts any person of an offence can declare that any medicine or scheduled substance in relation to the offence committed can be forfeited to the state. Any medicine or scheduled substance forfeited to the state must be destroyed or otherwise dealt with as the Director-General may direct.
The Code of Marketing Practice (Code)
A complainant can lodge a written, formal complaint with the Executive Officer of the Marketing Code Authority (MCA) setting out the details of the complaint. The respondent can then respond to the complaint. The complaint is then forwarded to the Adjudication Committee. Legal representation is only allowed if the Adjudication Committee considers it appropriate, based on the facts of the matter. If the Adjudication Committee finds in favour of the complainant, the Committee can impose one of the following sanctions:
A reprimand, caution or warning.
A fine (the amount is determined from time to time by the MCA).
A directive ordering the infringing party to audit its internal policies and procedures to be in line with those prescribed by the Code.
A directive prescribing that any offending promotional activity, material or advertisement is ceased and/or withdrawn.
An order that the infringing party provides a written undertaking that it will avoid similar breaches in future.
An order that the infringing party must make a public statement correcting its non-compliance with the Code.
An appropriate costs order, including the costs of the complainant.
Marketing to professionals
All forms of advertising and promotional activities must conform to the provisions of the Medicines Act and its Regulations. The following forms of marketing activities (although not exhaustive) to healthcare professionals (HCPs) are permitted:
Distribution of promotional material, including promotional aids and gifts.
Hosting or sponsoring meetings and events.
Reprints. Under the Code of Marketing Practice (Code), reprints of articles in journals must not be provided to any healthcare professional unless the articles have been published in a peer reviewed publication in line with good principles of scientific review and publication. When providing a reprint of an article about a health product, it must be accompanied by prescribing information.
Distribution of promotional material. Promotional material must only be sent or distributed to categories of persons whose need or interest in the particular information can reasonably be assumed.
A company must respect any requests by an addressee to cease or limit the volume of promotional material. Mailing lists must be kept up to date. Requests from healthcare professionals (HCPs) to be removed from promotional mailing lists must be complied with promptly and no name can be restored except at their request or with their permission.
Provision of hospitality
Companies, organisations or individuals are permitted to organise or sponsor meetings and events provided that:
The merit and focus of the meeting is clearly scientific and/or educational.
The venue and hospitality is secondary to the meeting (both in the allocation of time and focus).
The venue is appropriate and beneficial to the scientific or educational objectives and the purpose of the event or meeting.
Hospitality, meals and entertainment are modest. As a general rule, hospitality must not exceed what the HCPs would normally pay for themselves.
Invitations are not extended to spouses or other guests, except if they are HCPs or administrative staff and form part of the trainees or invited attendees at the meeting/event.
Inappropriate financial benefit or material benefits (including excessive hospitality) is not offered and/or extended to HCPs.
Reasonable payment and reimbursement for out-of-pocket expenses, including travel, are permissible for speakers (provided it is included in the terms of a written contract).
Meetings organised for patients, the general public, individual or groups of doctors, other HCPs and/or for administrative staff that are wholly or mainly of an entertainment, leisure, social or sporting nature are not permitted.
All advertising and/or promotional material must be based on the current approved South African package insert. Under the Medicines Act, the advertising and promotion of health products must:
Conform to the applicable regulations under the Medicines Act.
Form part of the promotional material and not be separate.
Be included in all promotional material (except for promotional items such as promotional aids, on which limited information must appear).
Be provided in a clear and legible manner.
Be consistent with the most recently approved package insert for the medicine.
The statement "For full prescribing information refer to the package insert approved by the medicines regulatory authority" must appear or be stated in all forms of advertising and/or promotion (written, audio, audio-visual and the internet, except for promotional items such as promotional aids).
The Code of Marketing Practice (Code) provides that a comparison in the marketing and promotion of health products is only permitted in promotional material if:
It is not misleading or disparaging.
Health products or services for the same needs or intended for the same purpose are compared.
One or more material, relevant and representative feature(s) are compared.
No confusion is created between the health product advertised and that of a competitor, or between the advertisers' trade marks, proprietary names, other distinguishing marks and those of a competitor.
The trade marks, proprietary names, other distinguishing marks, health products, services, activities or circumstances of a competitor are not discredited or defamed.
The trade marks or company names of another company are only mentioned with written permission from the other company.
No unfair advantage is taken of the reputation of a brand, trade mark, proprietary name or other distinguishing mark of another company.
Health products or services are not presented as imitations or replicas of goods or services bearing another company trade mark or trade name.
Hanging (open-ended) comparisons are not used.
Price comparisons must be accurate, fair and must not mislead.
The Medicine Act provides that no person can supply any medicine according to a bonus system, rebate system or any other incentive scheme.
The Code Marketing Practice (Code) provides that there must be no personal enrichment of healthcare professionals (HCPs) or other healthcare providers. No gift, benefit in kind, rebate, discount, kickback or any other pecuniary advantage can be offered or given to HCPs, administrative staff, government officials, or the general public as an inducement to prescribe, lease, loan, supply, stock, dispense, administer or buy any health product.
Discounts are not permitted under the Medicines Act.
The Medicines Act provides that no manufacturer or wholesaler or its agent can supply free of charge medicine to a pharmacist, medical practitioner, dentist, veterinarian, practitioner, nurse or other person registered under the Health Professions Act, 1974. This exclusion does not include the provision of medicine, free of charge, for the purposes of clinical trials, donations of medicines to the state, tendering to the state and quality control by inspectors.
Sponsorship of professionals
The sponsorship of professionals is regulated largely under the Code, particularly dealing with the attendance of HCPs at conferences or meetings.
The Code provides that the rationale for any meeting or sponsorship of a professional to attend a meeting must be transparent, valid and clear.
Payment of registration fees, travel and accommodation must be made to the professional associations/organisers and not directly to the HCP, unless proof is received that the amount spent is in the name of the sponsored person and corresponds to each and every line item as per the agreed sponsorship.
Sponsored speakers can receive reasonable payments.
Other promotional items or activities
Gifts. Occasional gifts to HCPs are acceptable provided that they are:
Inexpensive and of modest intrinsic value.
Not for personal use, for example, no entertainment CDs/DVDs, electronic items for entertainment, tickets to attend sporting events or other forms of entertainment.
Educational and/or of scientific value.
Competitions. Competitions must fulfil the following criteria:
The competition is based on medical/product knowledge or the acquisition of scientific knowledge.
The individual prizes or educational items offered are within the price limit set from time to time by the Marketing Code Authority (MCA).
Entry into a competition must not be dependent on prescribing, ordering or recommending a product and no such condition must be made or implied.
See Question 26.
Engagement with patient organisations
When companies provide financial support, significant indirect support and/or significant non-financial support to patient organisations, they must have in place a written agreement that states the amount of funding and also the purpose.
Use of logos and proprietary materials
The public use of a patient organisation's logo and/or proprietary material by a company requires written permission from that organisation.
Companies must not seek to influence the text of any patient organisation material that they sponsor in a manner that is favourable to their own commercial interests. This does not preclude companies from correcting factual inaccuracies.
Contracts between companies and patient organisations where they provide any type of services to companies are only allowed if the services are provided for the purpose of supporting healthcare or research.
Events and hospitality
All events sponsored or organised by or on behalf of a company including scientific, business or professional meetings must comply with the requirements that deal with the appropriate provision of hospitality and the hosting of meetings and events.
Hospitality can only be extended to persons who qualify as participants in their own right. In exceptional cases, in case of clear health needs (for example, disability), the travel meals, accommodation and registration fees of an accompanying person considered to be a care giver can be provided.
In 2008, amendments to the Medicines Act were passed by parliament and are known as the "Prelex" to the Medicines Act. The amendments provide for the:
Registration and regulation of medical devices.
Establishment of the South African Health Products Regulatory Authority (SAHPRA) (which will replace the current Medicines Control Council).
Appointment of a CEO of SAHPRA.
It was thought that the amendments would come into effect in mid 2013. However, the amendments, which still deal, to a large extent, with the registration, licensing, and advertising of medical devices, have not been passed or come into effect yet and it is uncertain when the Medicines Act will be amended.
The General Regulations to the Medicines Act were amended in November 2013 to include the registration of complementary medicines. The amendments, relating to the registration of complementary medicines came into effect in November 2013.
In July 2015, the Draft Regulations relating to Medical Devices and In Vitro Diagnostics were published under the Medicines Act for public comment. These Regulations have not yet entered into force. Once the Regulations have entered into force, the registration of medical devices with the Medicines Control Council (or its successor) will be compulsory. The Draft Regulations stipulate that only low/moderate risk medical devices can be advertised to the general public. It is unclear when these Regulations will be finalised and enacted.
Also, in July 2016, the Draft Amendments to the Medicines Act's General Regulations were published, for public comment. The Draft Amendments aim to amend the definition of a "complementary medicine" and to define "health supplement" (which will qualify as a complementary medicine). At this stage, it is unclear when these Amendments will be finalised and implemented.
Danie Dohmen, Partner
Adams & Adams
Professional qualifications. Attorney, South African High Court, 1988; Patent attorney, 2002; Notary public, 2004
Areas of practice. Patent and design litigation, commercialisation and opinion work.
Non-professional qualifications. BSc in physics and chemistry, 1993; LLB, 1996, Rand Afrikaans University
- Represented successful parties in the Supreme Court of Appeal and before the Constitutional Court in cases which set the current South African law on issues of inventiveness, clarity, interim injunctions in patent infringements, contributory patent infringement, the role of public interest in interim injunctions on patents for life-saving drugs, evidentiary requirements to prove patent infringement and requirements for divisional patent applications.
- Plays an active role in IP policy issues at a national and international level, and has represented national and foreign manufacturing groups in both national and international meetings, workshops and seminars on IP policy.
Alexis Apostolidis, Partner
Adams & Adams
Professional qualifications. Attorney, High Court of South Africa; Patent attorney, South Africa; Postgraduate diploma in EU competition law (merit), King's College, University of London
Areas of practice. Patent litigation and opinion work; competition law.
Non-professional qualifications. BSc in chemistry and law, bachelor of laws (cum laude), University of the Witwatersrand.
- Represented and advised clients such as Boehringer Ingelheim, GlaxoSmithKline, Eli Lilly, Sanofi-Aventis, AstraZeneca, Merck,FLSmidth and SASOL.
- Advised clients on competition law-related aspects of patent litigation, from the enforcement of patent rights to patent litigation settlements, and has advised on the competition law effects of certain commercial strategic practices concerning complex technologies and corresponding intellectual property.
- Advises industry associations in the current South African Healthcare Sector Enquiry.
Jenny Pienaar, Partner
Adams & Adams
Professional qualifications. Attorney, 1994; Trade mark practitioner, 2004
Areas of practice.Trade mark litigation, litigation relating to copyright, passing-off, unlawful competition, company name objections, litigation and advice relating to advertising, marketing and regulatory law, and related issues.
Non-professional qualifications. BA degree, University of Stellenbosch, 1988; LLB, University of Cape Town, 1991
Jeanette Visagie, Associate
Adams & Adams
Professional qualifications. Attorney, 2013; Trade mark practitioner, 2014
Areas of practice. Trade mark litigation, unlawful competition, passing off, copyright litigation, company name objections, litigation and advice relating to advertising, marketing and regulatory law, and related issues.
Non-professional qualifications. LLB, North-West University, 2009; LLM, North- West University and the University of Tilburg, 2011